Company: ABBV
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001551152-25-000029
Chunk: 15

Company: AbbVie Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
ITEM 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 

AbbVie Inc. and Subsidiaries

Condensed Consolidated Statements of Earnings (unaudited)

Three months endedMarch 31,(in millions, except per share data)20252024Net revenues$13,343 $12,310 Cost of products sold4,002 4,094 Selling, general and administrative3,293 3,315 Research and development2,067 1,939 Acquired IPR&D and milestones248 164 Total operating costs and expenses9,610 9,512 Operating earnings3,733 2,798 Interest expense, net627 453 Net foreign exchange loss4 4 Other expense, net1,441 586 Earnings before income tax expense1,661 1,755 Income tax expense372 383 Net earnings1,289 1,372 Net earnings attributable to noncontrolling interest3 3 Net earnings attributable to AbbVie Inc.$1,286 $1,369 Per share dataBasic earnings per share attributable to AbbVie Inc.$0.72 $0.77 Diluted earnings per share attributable to AbbVie Inc.$0.72 $0.77 Weighted-average basic shares outstanding1,768 1,769 Weighted-average diluted shares outstanding1,772 1,773 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2025 Form 10-Q | 1

AbbVie Inc. and Subsidiaries Condensed Consolidated Statements of Comprehensive Income (unaudited) 

Three months endedMarch 31,(in millions)20252024Net earnings$1,289 $1,372 Foreign currency translation adjustments, net of tax expense (benefit) of $17 for the three months ended March 31, 2025 and $(20) for the three months ended March 31, 2024487 (396)Net investment hedging activities, net of tax expense (benefit) of $(77) for the three months ended March 31, 2025 and $57 for the three months ended March 31, 2024(283)207 Pension and post-employment benefits, net of tax expense (benefit) of $0 for the three months ended March 31, 2025